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Introduction
The integrity of the human genome depends on numerous
processes that determine the fidelity of DNA replication. Several
of these are responsible for providing the replication machinery
with undamaged substrates with which to work (Figure 1, left).
For example, the modified nucleotide 8-oxo-dGTP generated by
oxidative stress is destroyed by enzymatic hydrolysis, thus pre-
venting its mutagenic incorporation during replication (Colussi
et al., 2002 and references therein). Endogenous cellular
metabolism and physical or chemical insult from the external
environment can damage the DNA. The resulting lesions come
in many different forms, including strand breaks and base mod-
ifications that can alter or eliminate correct base pairing poten-
tial. These lesions are usually repaired by base excision repair,
nucleotide excision repair, intrastrand crosslink repair, ssDNA
break repair or, for dsDNA breaks, nonhomologous end joining
(NHEJ). These repair processes provide undamaged DNA that
can be replicated accurately due to the high nucleotide selectiv-
ity and exonucleolytic proofreading activity of the replication
machinery (Figure 1, center). However, because DNA repair
processes are not perfect, the replication machinery occasion-
ally encounters problematic substrates, including lesions that
can block replication and can lead to double-strand DNA
breaks. These encounters require specialized translesion DNA
synthesis or homologous recombination to complete replica-
tion. Finally, modified and/or mismatched bases that are occa-
sionally incorporated during replication can be corrected after
replication (Figure 1, right) by specialized DNA repair process-
es that further reduce mutation rates.
The efficiency and fidelity with which these various DNA
transactions operate can be key to the origins of cancer. This is
beautifully illustrated by the affects of mutations that inactivate
the human MSH2 and MLH1 genes. The products of both these
genes are essential for DNA mismatch repair of replication
errors, and loss of this activity alters cellular responses to DNA-
damaging agents and strongly elevates mutation rates.
Inactivating mutations in MSH2 and MLH1 are responsible for
the majority of cases of hereditary non-polyposis colorectal
cancer and also increase susceptibility to cancer in several
other tissues.This linkage between mismatch repair gene muta-
tion, elevated mutation rate, and cancer is consistent with the
mutator hypothesis for cancer (reviewed in Loeb et al., 2003).
This hypothesis suggests that an early event in tumorigenesis is
a mutation that inactivates a gene that normally functions to
maintain genome stability,
resulting in an elevated
mutation rate. This elevat-
ed mutation rate in turn
results in additional muta-




tages that allow mutated
cells to expand and
achieve clonal dominance.
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Our appreciation of the DNA transactions that replicate and maintain a stable human genome is changing rapidly due to
recent discoveries indicating that eukaryotic cells contain many more DNA polymerases than previously thought.This review
describes emerging information on the properties and functions of human DNA polymerases, with emphasis on connections
between DNA polymerase functions and cancer.
Figure 1. DNA polymerase-
dependent processes that influ-
ence genome stability
See text for description. The Xs
within the diamond indicate
the presence of a lesion in DNA.
ssDNA means single-stranded
DNA and dNTP means deoxyri-
bonucleoside triphosphate.
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The validity of the mutator hypothesis, and the number and
types of cancers to which it may apply, is the subject of ongoing
debate, and several alternative points of view should be
carefully considered (e.g., see references in Loeb et al., 2003).
Regardless, given the association between cancer and failure to
correct DNA biosynthetic errors, it is interesting to note that the
processes mentioned above involve the synthesis of DNA by
various polymerases.Thus, it is logical to consider whether can-
cer is causally associated with mutations in DNA polymerase
genes that lower the efficiency of repair to leave potentially
mutagenic damage in DNA, or that reduce the fidelity of DNA
synthesis associated with replication, repair, or recombination.
Investigating relationships between cancer and polymerase
defects has become a much greater challenge due to the dis-
covery of a large number of DNA polymerases that were
unknown only a few years ago.
A veritable plethora of polymerases
Organisms from bacteria to man have long been known to con-
tain more than one DNA polymerase. The first mammalian DNA
polymerase was identified in 1960 and was later designated
with the first letter of the Greek alphabet as DNA polymerase α.
DNA polymerase α was at one time believed to be THE nuclear
replicative enzyme, but that view changed with the discovery of
additional polymerases. Through 1995, five mammalian DNA
polymerases had claimed Greek letters, DNA polymerases α, β,
γ, δ, and ε. Amazingly, it has taken only seven more years to dis-
cover nine additional DNA template-dependent DNA poly-
merases, all but one of which now has a Greek letter
designation (Table 1). This review focuses on very recent litera-
ture on these polymerases and emerging relationships between
DNA polymerase dysfunction and cancer. For additional cita-
tions related to the seminal discoveries and characterizations of
these DNA polymerases, interested readers can consult several
other reviews (e.g., Hübscher et al., 2002; Goodman, 2002;
Friedberg et al., 2002; Shcherbakova et al., 2003).
Defective proofreading by a replicative DNA polymerase
and cancer
The majority of DNA synthesis performed in a human cell is
replication of the six billion nucleotide nuclear genome.The bulk
of this polymerization is likely to be catalyzed by DNA poly-
merases δ, DNA polymerase ε, or both. These enzymes and
certain other polymerases in the B family insert correct
nucleotides onto correctly aligned primer templates while only
rarely generating mismatches that can lead to base substitution
and frameshift mutations. This high nucleotide selectivity
reflects dNTP-induced conformational changes in the DNA
polymerase and template primer that assemble a solvent-inac-
cessible dNTP binding pocket. This pocket snugly accommo-
dates nascent base pairs having normal Watson-Crick
geometry while excluding those that do not (Kunkel and
Bebenek, 2000; Kool, 2002).The catalytic subunits of DNA poly-
merases δ and ε also have intrinsic 3´ to 5´ proofreading (PR)
exonuclease activities that can excise base-base and inser-
tion/deletion mismatches generated by the polymerase. The
combination of nucleotide selectivity and proofreading accounts
for the remarkably high fidelity of DNA polymerases δ and ε
(Table 2), a property that is obviously key for faithful replication
of the large nuclear genome. Current evidence suggests that, in
addition to their roles in replication, DNA polymerases δ and ε
fill gaps in DNA generated during nucleotide repair (NER), mis-
match repair (MMR), and possibly base excision repair (BER).
The important role for the 3´ to 5´ exonuclease of DNA poly-
merase δ in suppressing tumorigenesis is clearly illustrated by
the phenotypes of mice with a POLD1 gene mutation that inac-
tivates the exonuclease activity of DNA polymerase δ (Goldsby
et al., 2002). This mutation results in loss of PR, a recessive
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Table 1. DNA Template-dependent human DNA polymerases
DNA polymerase Gene (alias) Polymerase family Chromosomal location Associated activities
α (alpha) POLA B Xp21.3–22.1 RNA primase
β (beta) POLB X 8p11.2 dRP lyase and AP lyase
γ (gamma) POLG A 15q25 3′ to 5′ exo, dRP lyase
δ (delta) POLD1 B 19q13.3 3′ to 5′ exo
ε (epsilon) POLE B 12q24.3 3′ to 5′ exo
ζ (zeta) POLZ (REV3) B 6q21
η (eta) POLH (XPV, RAD30A) Y 6p21.1
θ (theta) POLQ A 3q13.3
ι (iota) POLI (RAD30B) Y 18q21.1 dRP lyase
κ (kappa) POLK (DINB1) Y 5q13
λ (lambda) POLL X 10q23 dRP lyase
µ (mu) POLM X 7p13 terminal transferase
σ (sigma) POLS (TRF4-1) X 5p15 3′ to 5′ exo
Rev1 REV1 Y 2q11.1–11.2 deoxycytidine transferase
Not listed is the template-independent enzyme terminal deoxynucleotide transferase, or telomerase, the ribonucleoprotein that adds TTAGGG repeats
onto the ends of chromosomes.
Table 2. Error rates of mammalian DNA polymerases
Error rate × 10−5
DNA Proofreading 
polymerase exonuclease Substitutions −1 deletions
Pol δ Yes ?1 2
Pol ε Yes ≤1 ≤0.5
Pol γ Yes ≤1 0.6
Pol α No 16 3
Pol β No 67 13
Pol κ No 580 180
Pol η No 3500 240
Pol ι No 72,000 (T•dGTP) —
Shown are average single base error rates per nucleotide incorporated for
gap filling DNA synthesis in vitro, as measured using M13mp2 fidelity assays.
For further details, see references in Kunkel et al., 2003.
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mutator phenotype, and a recessive cancer phenotype charac-
terized by reduced life span (median survival, 10 months) and
several different tumor types of epithelial cell origin.This implies
that DNA polymerase errors that escape correction by PR con-
tribute to carcinogenesis, preferentially in epithelial tissues.
Thus, loss of proofreading during replication, like loss of MMR
after replication, generally conforms to the mutator hypothesis
for cancer. Interestingly, PR-deficient and MMR-deficient mice
develop different types of tumors arising from somewhat differ-
ent cell populations. These differences may reflect the
sequence composition of the target genes that are mutated
upon loss of these two distinctly different error correction
processes. For example, a well-known mutational signature for
loss of MMR is microsatellite instability (MSI).This form of insta-
bility likely initiates with DNA strand slippage. When this occurs
during replication of long repetitive sequences, the misaligned
intermediate can be stabilized by numerous correct base pairs,
and the unpaired bases are far removed from the primer termi-
nus. This effectively promotes polymerization, which requires a
duplex primer terminus, and reduces the efficiency proofread-
ing because the exonuclease digests single-stranded DNA
(reviewed in Bebenek and Kunkel, 2000). This leaves MMR as
the major guardian against MSI. The risk that a target gene
involved in multistage carcinogenesis will be altered by a
frameshift mutation in an MMR-deficient cell will increase as the
repetitive sequence content of its open reading frame increas-
es. However, the relationship between mutational risk and loss
of proofreading should be quite different. This is because PR
removes replication errors that are directly at or within very few
base pairs of the primer terminus and can therefore more read-
ily enter the exonuclease active site as single-stranded DNA.
Thus a PR defect in a major replicative DNA polymerase places
all genes at increased risk, especially for base substitutions and
for frameshifts in short repeats. The increase in risk due to a
proofreading defect will vary somewhat depending on the
nucleotide selectivity of the DNA polymerase that generated the
mismatch, the type of mismatch (12 base-base mismatches are
possible), and the local sequence environment (for further
details, see Kunkel and Bebenek, 2000). Thus, the fact that PR
and MMR are distinct processes whose efficiencies depend on
different parameters naturally places different genes at risk for
mutations involved in multistage carcinogenesis.
The tissue specificity of cancers due to loss of MMR is sug-
gested to reflect both an increased mutation rate and altered
cellular responses to DNA damage. In a similar manner, differ-
ences in the cancer phenotypes of PR-deficient mice may
reflect loss of other functions performed by 3´ to 5´ exonucleas-
es. For example, the mutator phenotype observed in yeast upon
inactivation of the 3´ to 5´ exonuclease of DNA polymerase δ
depends on the S phase checkpoint (Datta et al., 2000). Also,
the 3´ to 5´ exonuclease activity of DNA polymerase δ can
excise displaced DNA flaps during lagging strand replication,
and failure to do so can result in duplications (Jin et al., 2001).
For these reasons, it will be interesting to investigate the car-
cinogenic consequences of concomitant loss of PR and MMR.
Since these operate in series to correct DNA polymerase errors
and stabilize the genome, polymorphisms in proofreading or
MMR genes that have little or no effect alone may have serious
consequences if combined.
Defective translesion DNA synthesis and skin cancer
Human DNA polymerase η is one of four human polymerases
(Table 1) in the Y family. Pol η is encoded by the XPV (PolH)
gene (reviewed in Prakash and Prakash, 2002), and persons
with mutations that inactivate polymerase η suffer from
Xeroderma pigmentosum, one symptom of which is greatly
increased susceptibility to sunlight-induced skin cancer. This
relationship is thought to reflect the ability of DNA polymerase η
to efficiently copy a DNA template containing a cyclobutane
pyrimidine dimer (CPD), a major sunlight-induced lesion that
distorts DNA. This translesion synthesis (TLS) ability of DNA
polymerase η is remarkable because highly efficient bypass of
bulky lesions was not seen in many years of studying other DNA
polymerases in families A, B, and X. The current hypothesis for
the connection between skin cancer and loss of DNA poly-
merase η in XPV patients is that, unlike certain other UV photo-
products, CPDs are slowly removed by excision repair and
therefore sometimes encountered by the replication machinery.
CPDs block DNA synthesis by accurate replicative polymerases
like Pol δ or ε, while Pol η efficiently performs TLS that avoids
generating CPD-induced mutations. In the absence of Pol η, as
is the case in XPV patients, CPDs are bypassed in a manner
that generates the mutations that lead to skin cancer. Two
enzymes suggested to catalyze this backup bypass reaction are
DNA polymerases ι and ζ (Table 1), neither of which has a
proofreading activity. DNA polymerase ι has several interesting
properties, among which is the ability to efficiently insert
nucleotides opposite certain lesions, but without efficiently
extending the resulting primer terminus. However, DNA poly-
merase ζ, a family B member encoded by the REV3 gene
(Lawrence and Maher, 2001), can extend mismatched primer
termini efficiently, and genetic evidence reveals that REV3 is
required for ultraviolet light-induced UV mutagenesis. This has
led to a “two-polymerase” bypass model (see Woodgate, 2001;
Prakash and Prakash, 2002; Bresson and Fuchs, 2002, and ref-
erences therein), wherein the first enzyme inserts a nucleotide
opposite a lesion and a second enzyme extends that substrate
to complete lesion bypass.
The multipolymerase TLS models are likely to be relevant to
other human Y family members implicated in TLS, including
DNA polymerase κ and REV1 (Table 1). Like DNA polymerase
η, DNA polymerase κ alone can efficiently bypass certain bulky
lesions that distort DNA, but its TLS specificity is somewhat dif-
ferent than that of DNA polymerase η (see references in
Shcherbakova et al., 2003). For example, DNA polymerase κ
can bypass a benzo[a]pyrene diol epoxide (BPDE) adduct on
the N2 of guanine. This bypass primarily involves insertion of
dCMP, an event that would avoid benzo[a]pyrene-induced muta-
tions. This is interesting because expression of the mouse PolK
gene is under the control of the arylhydrocarbon receptor
(AhR), a crucial factor for activation of benzo[a]pyrene into
BPDE in mammalian cells. This has led to the suggestion that
DNA polymerase κ participates in bypassing lesions generated
by polycyclic aromatic hydrocarbons (PAH) in a manner that
avoids mutations (see Ogi et al., 2002 and references therein).
Perhaps also relevant to the two-polymerase model is REV1, a
partially template-dependent DNA polymerase that preferential-
ly adds dCMP to primer termini. This protein interacts with
REV3 and it is required for mutagenesis induced by some
agents that induce DNA damage (Lawrence and Maher, 2001;
Goodman, 2002).
The fact that 3 (Pols α, δ, and ε) of the 14 enzymes listed in
Table 1 are required for normal replication of undamaged
nuclear DNA and that at least 5 others (Pols ζ, η, κ, ι, and
REV1) are implicated in TLS has led to the “factory model”
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(Goodman, 2002). The hypothesis is that many polymerases
may be present in a large replication complex, and the TLS
enzymes are only called upon when the major replicative poly-
merases are blocked, either by a lesion or a naturally occurring
undamaged barrier to replication, such as an unusual DNA
structure. After performing their tasks, the TLS enzymes leave
the template primer to allow resumption of synthesis by the
major replicative DNA polymerases. Whether present in a facto-
ry or dispersed throughout the nucleus (e.g., see Kannouche et
al., 2001), we do not yet know exactly how polymerases can
switch as needed. Switching will undoubtedly require interac-
tions between a polymerase catalytic subunit or accessory sub-
unit (Hübscher et al., 2002) and other proteins (e.g., PCNA,
RPA). These interactions can involve domains of DNA poly-
merases not required for polymerase activity per se (e.g., see
Kannouche et al., 2002). Striking examples of catalytic subunits
of human DNA polymerases that are much larger than needed
to encode only their polymerization activity include Pol ε (255
kDa) and Pol ζ (353 kDa). Indeed, carboxy-terminal residues
well beyond those encoding the polymerase and exonuclease
activities of DNA polymerase ε are essential for cell cycle
checkpoint control (see Datta et al., 2000 and Shcherbakova et
al., 2003 for further discussion of polymerases and check-
points). At least theoretically, such residues are potential targets
for mutations leading to loss of checkpoint control in tumors.
Analyses of protein-protein interactions and structure-function
studies of the polymerase, exonuclease, AP lyase, and dRP
lyase activities of DNA polymerases have now matured to the
point where it is feasible to efficiently investigate possible
associations between cancer and putative functional poly-
morphisms in the genes encoding DNA polymerases (e.g., see
http://www.niehs.nih.gov/envgenom/snpsdb.htm).
Exonuclease-deficient DNA polymerases with specialized
functions
Given the importance of proofreading to genome stability and
the consequences of losing 3´ to 5´ exonuclease activity men-
tioned above, it is interesting that the majority of the human DNA
polymerases listed in Table 1 actually lack intrinsic 3´ to 5´
exonuclease activity and cannot proofread the errors they make.
Current evidence indicates that these DNA polymerases have
specialized functions involving synthesis of relatively short DNA
chains (reviewed further in Shcherbakova et al., 2003; Kunkel et
al., 2003). For example, DNA polymerase α is a member of fam-
ily B with an associated primase that is used to start replication
of Okazaki fragments. Even without proofreading, the nucleotide
selectivity of DNA polymerase α alone is sufficient for relatively
accurate DNA synthesis (Table 2). It is also possible that an
exonuclease encoded by a different gene may proofread errors
made by exonuclease-deficient DNA polymerases. For example,
the average base substitution error rate of DNA polymerase β
alone (Table 2) is sufficient to introduce more than one mismatch
per day into the genome during repair of the ≥10,000 damaged
bases estimated to arise in 24 hr. However, the apurinic endonu-
clease that incises the DNA backbone following DNA glycosy-
lase removal of a damaged base contains an intrinsic 3´ to 5´
exonuclease that can preferentially excise mismatched bases
from primer termini (Chou and Cheng, 2002). Thus, errors made
by DNA polymerase β during BER might be proofread by this
exonuclease.This could be important for preventing the accumu-
lation of mismatches in the human genome, perhaps especially
for quiescent cells subject to stresses that result in damage
repaired by BER, e.g., oxidative stress.
To fulfill its specialized function in BER that replaces a sin-
gle damaged nucleotide (e.g., removal of U from a G-U mis-
match arising from cytosine deamination), DNA polymerase β
has an intrinsic dRP lyase activity that excises the 5´-deoxyri-
bosephosphate group produced by APE incision. DNA poly-
merase γ has a dRP lyase activity that could serve a similar role
in repair of the mitochondrial genome. Curiously, human DNA
polymerases ι and λ also have an intrinsic dRP lyase activity.
This implies that repair that requires removal of a sugar-phos-
phate may be performed by more than one DNA polymerase,
with the choice of which polymerase to use perhaps depending
on the cell type, damaged substrate, or timing of DNA repair.
For example, DNA polymerase ι may participate in removing
uracil from DNA when it is incorporated opposite adenine dur-
ing replication using dUTP pools (Kunkel et al., 2003). In addi-
tion to functional redundancy, quite different functions may be
performed by even closely related human DNA polymerases.
For example, DNA polymerase λ is an X family enzyme with
homology to and some properties in common with DNA poly-
merase β. DNA polymerase λ is also homologous to yeast DNA
polymerase IV, which participates in NHEJ of double-stranded
breaks in DNA (Tseng and Tomkinson, 2002 and references
therein). This has cancer implications because defects in NHEJ
are associated with cancer (Tlsty, 2002). Thus, human poly-
merases not yet directly implicated in disease may eventually
be found to be relevant to cancer by virtue of possible functions
such as repair of DNA crosslinks by DNA polymerase θ
(reviewed in Shcherbakova et al., 2003) or participation in sister
chromatid cohesion by DNA polymerase σ (Carson and
Christman, 2001).
Amazingly inaccurate DNA polymerases
In contrast to the other exonuclease-deficient DNA polymeras-
es listed in Table 2, members of the Y family that also lack
proofreading have much lower base substitution and
frameshift fidelity when copying undamaged templates (Table
2). In fact, DNA polymerase η error rates are similar to what
was predicted over 20 years ago if a polymerase acted as a
mere zipper without closely checking for correct base pair
geometry. The fidelity of DNA polymerase κ is almost as low,
and DNA polymerase ι has the truly amazing ability to gener-
ate some mismatches (e.g., T-dGTP, Table 2) at rates similar to
or even higher than correct base pairs. The low fidelity of the Y
family DNA polymerases that are implicated in TLS suggests
that relaxed geometric selectivity may be important for effi-
cient bypass of template lesions that distort helix geometry.
Consistent with this, Sulfolobus sulfataricus DNA polymerase
4, a homolog of human Pol κ with similarly low fidelity, has an
open and solvent accessible active site that can even accom-
modate two template bases at once, one of which is unpaired
(Ling et al., 2001). Structural studies of Y family DNA poly-
merases (reviewed in Boudsocq et al., 2002; Friedberg et al.,
2001) also reveal a fourth polymerase subdomain not found in
polymerases in families A, B, and X, which interacts with DNA
and may be critical for TLS efficiency and specificity. The exis-
tence of several human polymerases with very low fidelity sug-
gests the need for careful regulation of their functions by
protein-protein interactions, transcriptional and/or translation-
al control. That permanent or transient loss of regulation of a
DNA polymerase may be relevant to human cancer is sug-
gested by the tumorigenic consequences of ectopic expres-
sion of DNA polymerase β in mice (Bergoglio et al., 2002 and
references therein).
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Promiscuous polymerases, somatic hypermutation, cyto-
sine deamination, and cancer
In the field of cancer research, mutations are considered to be
detrimental to health. However, normal human B cells in germi-
nal centers are thought to conduct an inaccurate DNA transac-
tion that results in mutations beneficial to health, somatic
hypermutation (SHM) of DNA encoding the variable (antigen
binding) regions of the heavy and light chain immunoglobulin
genes. SHM occurs at a rate that is much higher than the over-
all rate of spontaneous mutation rate in the nuclear genome,
suggesting that targeted, highly inaccurate DNA synthesis is
occurring. The human Y family polymerases are prime candi-
dates for contributing to SHM due to their low fidelity, as is Pol ζ,
by virtue of its promiscuous ability to extend mismatches.
Indeed, several recent observations suggest the possible
involvement of DNA polymerases ζ, η, and ι in SHM (see
Kunkel et al., 2003 and numerous references therein).
The types of replication and/or repair transactions possibly
involved in SHM are the subject of active investigation and con-
siderable speculation. SHM and class switch recombination
(CSR), a second process involved in immune system develop-
ment, require activation-induced cytidine deaminase (AID). AID
belongs to a family of proteins that includes the apolipoprotein B
mRNA editing catalytic subunit 1 (APOBEC1). APOBEC1 edits
mRNA in gastrointestinal tissues by deaminating a particular
cytosine to uracil to create a stop codon. It was recently discov-
ered that AID (Petersen-Mahrt et al., 2002), APOBEC1, and two
related Apobec proteins (Harris et al., 2002) are all mutagenic
when expressed in E. coli. The induced mutations are C•G to
T•A transitions whose frequencies are substantially higher in
cells lacking uracil DNA glycosylase, indicating that these pro-
teins enzymatically deaminate cytosine to produce uracil in
DNA. The mutagenic potential of uracil is particularly high
because, unlike the blocking lesions mentioned above that
require TLS polymerases, uracil can be efficiently replicated like
normal thymine to yield C to T base substitution mutations.
What might this have to do with cancer? In addition to beneficial
functions like SHM and RNA editing, AID and Apobec could
potentially produce widespread genomic instability if enzymatic
deamination is not controlled properly. This is an alternative to
aberrant mRNA editing for explaining why transgenic expres-
sion of APOBEC1 in mice leads to liver cancer (Yamanaka et
al., 1995). Indeed, Neuberger and colleagues report examples
wherein expression of Apobec-1 and Apobec3G is high in tumor
tissue but not in normal tissue (Harris et al., 2002).Thus, unreg-
ulated expression of cytidine deaminase family members could
possibly result in cytosine deamination-dependent mutagenesis
that contributes to carcinogenesis, again consistent with the
mutator hypothesis for multistage carcinogenesis.
Closing thoughts
Cancer is now associated with mutagenic replication of dam-
aged DNA resulting from loss of Pol η, with defective proofread-
ing by Pol δ and with defective mismatch repair of errors made
by replicative DNA polymerases. These three examples have in
common the loss of a replication fidelity function that elevates
the mutation rate without loss of the replication efficiency need-
ed for clonal expansion of mutant cells to give rise to a tumor.
Given the existence of many DNA polymerases whose fidelity
can vary over a 10,000-fold range (Table 2), and given the mul-
tiple and complex transactions that all require DNA synthesis to
maintain genome stability, there are probably many more ways
to generate mutant cells that thrive despite reduced DNA syn-
thesis fidelity. Thus, the current list of associations between
defective DNA synthesis fidelity and cancer is almost certainly
incomplete. How cells regulate which DNA polymerase is used
for which DNA transaction and substrate, the accessory protein
partnerships, and mechanisms used for polymerase switching
or to prevent catalysis at the wrong place or time, and whether
additional polymerase gene mutations or functional polymor-
phisms exist that are relevant to carcinogenesis are issues for
the future. The opportunity and the challenge are great, given
the number of polymerases, the sequence complexity of the
human genome, and the large number of different DNA adducts
that can result from endogenous cellular metabolism and from
external exposure to physical and chemical carcinogens.
Selected reading
Bebenek, K., and Kunkel, T.A. (2000). Cold Spring Harb. Symp. Quant. Biol.
LXV, 81–91.
Bergoglio, V., Pillaire, M.-J., Lacriox-Triki, M., Raynaud-Messina, B., Canitrot,
Y., Bieth, A., Garès, M., Wright, M., Delsol, G., Loeb, L.A., et al. (2002).
Cancer Res. 62, 3511–3514.
Boudsocq, F., Ling, H., Yang, W., and Woodgate, R. (2002). DNA Repair 1,
343–358.
Bresson, A., and Fuchs, R.P.P. (2002). EMBO J. 21, 3881–3887.
Carson, D.R., and Christman, M.F. (2001). Proc. Natl. Acad. Sci. USA 98,
8270–8275.
Chou, K.M., and Cheng, Y.C. (2002). Nature 415, 655–659.
Colussi, C., Parlanti, E., Degan, P., Aquillina, G., Barnes, D., Macpherson, P.,
Karran, P., Crescenzi, M., Dogliotti, E., and Bignami, M. (2002). Curr. Biol. 12,
912–918.
Datta, A., Schmeits, J.L., Amin, N.S., Lau, P.J., Myung, K., and Kolodner,
R.D. (2000). Mol. Cell 6, 593–603.
Friedberg, E.C., Fischhaber, P.L., and Kisker, C. (2001). Cell 107, 9–12.
Friedberg, E.C., Wagner, R., and Radman, M. (2002). Science 296,
1627–1630.
Goldsby, R.E., Hays, L.E., Chen, X., Olmsted, E.A., Slayton, W.B.,
Spangrude, G.J., and Preston, B.D. (2002). Proc. Natl. Acad. Sci. USA 99,
15560–15565.
Goodman, M.F. (2002). Annu. Rev. Biochem. 71, 17–50.
Harris, R.S., Petersen-Mahrt, S.K., and Neuberger, M.S. (2002). Mol. Cell 10,
1247–1253.
Hübscher, U., Maga, G., and Spadari, S. (2002). Annu. Rev. Biochem. 71,
133–163.
Jin, Y.H., Obert, R., Burgers, P.M.J., Kunkel, T.A., Resnick, M.A., and
Gordenin, D.A. (2001). Proc. Natl. Acad. Sci. USA 98, 5122–5127.
Kannouche, P., Broughton, B.C., Volker, M., Hanaoka, F., Mullanders, L.H.,
and Lehmann, A.R. (2001). Genes Dev. 15, 158–172.
Kannouche, P., Fernandez de Henestrosa, A.R., Coull, B., Vidal, A.E., Gray,
C., Zicha, D., Woodgate, R., and Lehmann, A.R. (2002). EMBO J. 21, 1–11.
Kool, E.T. (2002). Annu. Rev. Biochem. 71, 191–219.
Kunkel, T.A., and Bebenek, K. (2000). Annu. Rev. Biochem. 69, 497–529.
Kunkel, T.A., Pavlov, Y.I., and Benenek, K.A. (2003). DNA Repair 2, 135–149.
Lawrence, C.W., and Maher, V.M. (2001). Philos. Trans. R. Soc. Lond. B Biol.
Sci. 356, 41–46.
Ling, H., Boudsocq, F., Woodgate, R., and Yang, W. (2001). Cell 107, 91–102.
Loeb, L., Loeb, K., and Anderson, J.P. (2003). Proc. Natl. Acad. Sci. USA 100,
776–781.
Ogi, T., Shinkai, Y., Tanaka, K., and Ohmori, H. (2002). Proc. Natl. Acad. Sci.
USA 99, 15548–15553.
M I N I R E V I E W
110 CANCER CELL : FEBRUARY 2003
Petersen-Mahrt, S.K., Harris, R.S., and Neuberger, M.S. (2002). Nature 418,
99–103.
Prakash, S., and Prakash, L. (2002). Genes Dev. 16, 1872–1883.
Shcherbakova, P.V., Bebenek, K., and Kunkel, T.A. (2003). Science of Aging
Knowledge Environment, in press.
Tlsty, T.D. (2002). Cancer Cell 2, 2–4.
Tseng, H.-M., and Tomkinson, A.E. (2002). J. Biol. Chem. 277,
45630–45637.
Woodgate, R. (2001). Mutat. Res. 485, 83–92.
Yamanaka, S., Balestra, M.E., Ferrell, L.D., Fan, J., Arnold, K.S., Taylor, S.,
Taylor, J.M., and Innerarity, T.L. (1995). Proc. Natl. Acad. Sci. USA 92,
8483–8487.
M I N I R E V I E W
